Global pharma major Lupin Limited (Lupin) announced the launch of liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen, in the United States.
Liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients aged 10 years and older, with type 2 diabetes mellitus.
Liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen (RLD Victoza) had an estimated annual sale of USD 350 million in the US (IQVIA MAT Aug 2025).
Spiro Gavaris, president – US generics, Lupin, said, “We are pleased to launch liraglutide injection in the US. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.” |